Deere John Starter F620 M665 M655 M653 LX266 LX255 LX173 F687 F680 Car & Truck Starters


  1. Home
  2. Deere John Starter F620 M665 M655 M653 LX266 LX255 LX173 F687 F680
  1. facebook
  2. twitter
  3. linkedin
  4. pinterest
Starter John Deere F620 F680 F687 LX173 LX255 LX266 M653 M655 M665
Condition: New Core Charge: 0
Brand:

Premier

Interchange Part Number: 9722809-264, AM018390, AM108390, AM124993, AM131296, 12-098-03, 24-098-01, K0H2409801
Fitment Type: Direct Replacement Manufacturer Part Number:

128000-748

Warranty: 1 Year Other Part Number: 128000-7480, 228000-264, 228000-2640, 228080-2640
UPC:

689231872145



published on tue nov 09 2021

Deere John Starter F620 M665 M655 M653 LX266 LX255 LX173 F687 F680 Car & Truck Starters

gandhi, s., klein, j., robertson, a., pena-hernandez, m. a.,

Deere John Starter F620 M665 M655 M653 LX266 LX255 LX173 F687 F680 Car & Truck Starters

lin, m. j., roychoudhury, p., lu, p., fournier, j., ferguson, d., mohamed bakhash, s. a., muenker, m. c., srivathsan, a., wunder, e. a., kerantzas, n., wang, w., pyle, a., wilen, c. b., ogbuagu, o., greninger ,, a. l., iwasaki, a., schulz, w. l., ko, a. i.

sars-cov-2 remdesivir resistance mutations have been generated in vitro but have not been reported in patients receiving treatment with the antiviral agent. we present a case of an immunocompromised patient with acquired b-cell deficiency who developed an indolent, protracted course of sars-cov-2 infection. remdesivir therapy alleviated symptoms and produced a transient virologic response, but her course was complicated by recrudescence of high-grade viral shedding. whole genome sequencing identified a mutation, e802d, in the nsp12 rna-dependent rna polymerase which was not present in pre-treatment specimens. in vitro experiments demonstrated that the mutation conferred a ~6-fold increase in remdesivir ic50 but resulted in a fitness cost in the absence of remdesivir. sustained clinical and virologic response was achieved after treatment with casirivimab-imdevimab. although the fitness cost observed in vitro may limit the risk posed by e802d,

, this case illustrates the importance of monitoring for remdesivir resistance and the potential benefit of combinatorial therapies in immunocompromised patients with sars-cov-2 infection.

509
1.2k
EVGENIA.RU RSS